Literature DB >> 30392802

Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease.

Barbara Geeroms1, Gert De Hertogh2, Ragna Vanslembrouck1, Hans Wildiers3, Frederik Nevens4, Geert Maleux5.   

Abstract

Three patients with a medical history of breast carcinoma and metastatic carcinomatous liver disease associated with severe portal hypertension and refractory ascites are presented. Transjugular intrahepatic portosystemic shunt creation was considered as a palliative treatment option and a valuable alternative to regular paracenteses in these patients. In 2 of the 3 patients, the refractory ascites was controlled for several months without need for paracentesis, and subsequently transjugular intrahepatic portosystemic shunt may provide valuable palliation and ascites control in patients with refractory ascites due to breast cancer-induced pseudocirrhosis.
Copyright © 2018 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30392802     DOI: 10.1016/j.jvir.2018.08.007

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  3 in total

1.  Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.

Authors:  Lauren A Shreve; Cathal O'Leary; Timothy W I Clark; S William Stavropoulos; Michael C Soulen
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases.

Authors:  Kazuhide Takata; Ai Mogi; Ryo Yamauchi; Satoshi Shakado; Fumihito Hirai
Journal:  Cureus       Date:  2022-05-25

3.  Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity.

Authors:  Dan Engelman; Michel Moreau; Antonia Lepida; Yasmine Zaouak; Marianne Paesmans; Ahmad Awada
Journal:  ESMO Open       Date:  2020-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.